Investigating whether serum IGF-1 and IGFBP-3 levels reflect the height outcome in prepubertal children upon rhGH therapy: LG growth study database

Serum insulin-like growth factor-1 (IGF-I) and IGF binding protein-3 (IGFBP-3) levels can be used to monitor the safety of recombinant human growth hormone (rhGH) therapy. In this study, we evaluated the changes in serum IGF-I and IGFBP-3 levels during rhGH therapy as a marker of height outcome in p...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Minsun Kim, Eun Young Kim, Cheol Hwan So, Chan Jong Kim
Formato:	article
Lenguaje:	EN
Publicado:	Public Library of Science (PLoS) 2021
Materias:	Medicine R Science Q
Acceso en línea:	https://doaj.org/article/ea54cec9de4f4f20af2fbf43945bfda5
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:ea54cec9de4f4f20af2fbf43945bfda5
record_format	dspace
spelling	oai:doaj.org-article:ea54cec9de4f4f20af2fbf43945bfda52021-11-11T06:44:22ZInvestigating whether serum IGF-1 and IGFBP-3 levels reflect the height outcome in prepubertal children upon rhGH therapy: LG growth study database1932-6203https://doaj.org/article/ea54cec9de4f4f20af2fbf43945bfda52021-01-01T00:00:00Zhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC8559946/?tool=EBIhttps://doaj.org/toc/1932-6203Serum insulin-like growth factor-1 (IGF-I) and IGF binding protein-3 (IGFBP-3) levels can be used to monitor the safety of recombinant human growth hormone (rhGH) therapy. In this study, we evaluated the changes in serum IGF-I and IGFBP-3 levels during rhGH therapy as a marker of height outcome in prepubertal children. Totally, 705 prepubertal children with short stature were enrolled from the LG Growth Study Database. Data for three groups of subjects were obtained as follows: Idiopathic GH deficiency (IGHD; n = 486); idiopathic short stature (n = 66); small for gestational age (n = 153). Serum IGF-I and IGFBP-3 levels at the baseline and after the 1st and 2nd year of rhGH therapy, as well as the Δheight standard deviation score (SDS), were obtained. Δheight SDS after the 1st and 2nd year of rhGH therapy had notably increased compared to that at the baseline for all three groups. IGF-I and IGFBP-3 levels in all three groups were significantly increased compared to those at the baseline (p <0.001). Δheight SDS was positively correlated with ΔIGF-1 SDS after the 1st year of therapy, ΔIGFBP-3 SDS after the 2nd year of therapy in the IGHD group, and ΔIGF-I SDS and ΔIGFBP-3 SDS after the 2nd year of therapy (p < 0.05), regardless of whether the height at the baseline was a covariate. The increase in IGF-I and IGFBP-3 levels during rhGH therapy was related to the growth response in children with IGHD. Therefore, it may be valuable to measure the change in serum IGF-I and IGFBP-3 levels, especially the latter, during rhGH treatment to predict the growth response upon long-term treatment.Minsun KimEun Young KimEun Young KimCheol Hwan SoChan Jong KimPublic Library of Science (PLoS)articleMedicineRScienceQENPLoS ONE, Vol 16, Iss 11 (2021)
institution	DOAJ
collection	DOAJ
language	EN
topic	Medicine R Science Q
spellingShingle	Medicine R Science Q Minsun Kim Eun Young Kim Eun Young Kim Cheol Hwan So Chan Jong Kim Investigating whether serum IGF-1 and IGFBP-3 levels reflect the height outcome in prepubertal children upon rhGH therapy: LG growth study database
description	Serum insulin-like growth factor-1 (IGF-I) and IGF binding protein-3 (IGFBP-3) levels can be used to monitor the safety of recombinant human growth hormone (rhGH) therapy. In this study, we evaluated the changes in serum IGF-I and IGFBP-3 levels during rhGH therapy as a marker of height outcome in prepubertal children. Totally, 705 prepubertal children with short stature were enrolled from the LG Growth Study Database. Data for three groups of subjects were obtained as follows: Idiopathic GH deficiency (IGHD; n = 486); idiopathic short stature (n = 66); small for gestational age (n = 153). Serum IGF-I and IGFBP-3 levels at the baseline and after the 1st and 2nd year of rhGH therapy, as well as the Δheight standard deviation score (SDS), were obtained. Δheight SDS after the 1st and 2nd year of rhGH therapy had notably increased compared to that at the baseline for all three groups. IGF-I and IGFBP-3 levels in all three groups were significantly increased compared to those at the baseline (p <0.001). Δheight SDS was positively correlated with ΔIGF-1 SDS after the 1st year of therapy, ΔIGFBP-3 SDS after the 2nd year of therapy in the IGHD group, and ΔIGF-I SDS and ΔIGFBP-3 SDS after the 2nd year of therapy (p < 0.05), regardless of whether the height at the baseline was a covariate. The increase in IGF-I and IGFBP-3 levels during rhGH therapy was related to the growth response in children with IGHD. Therefore, it may be valuable to measure the change in serum IGF-I and IGFBP-3 levels, especially the latter, during rhGH treatment to predict the growth response upon long-term treatment.
format	article
author	Minsun Kim Eun Young Kim Eun Young Kim Cheol Hwan So Chan Jong Kim
author_facet	Minsun Kim Eun Young Kim Eun Young Kim Cheol Hwan So Chan Jong Kim
author_sort	Minsun Kim
title	Investigating whether serum IGF-1 and IGFBP-3 levels reflect the height outcome in prepubertal children upon rhGH therapy: LG growth study database
title_short	Investigating whether serum IGF-1 and IGFBP-3 levels reflect the height outcome in prepubertal children upon rhGH therapy: LG growth study database
title_full	Investigating whether serum IGF-1 and IGFBP-3 levels reflect the height outcome in prepubertal children upon rhGH therapy: LG growth study database
title_fullStr	Investigating whether serum IGF-1 and IGFBP-3 levels reflect the height outcome in prepubertal children upon rhGH therapy: LG growth study database
title_full_unstemmed	Investigating whether serum IGF-1 and IGFBP-3 levels reflect the height outcome in prepubertal children upon rhGH therapy: LG growth study database
title_sort	investigating whether serum igf-1 and igfbp-3 levels reflect the height outcome in prepubertal children upon rhgh therapy: lg growth study database
publisher	Public Library of Science (PLoS)
publishDate	2021
url	https://doaj.org/article/ea54cec9de4f4f20af2fbf43945bfda5
work_keys_str_mv	AT minsunkim investigatingwhetherserumigf1andigfbp3levelsreflecttheheightoutcomeinprepubertalchildrenuponrhghtherapylggrowthstudydatabase AT eunyoungkim investigatingwhetherserumigf1andigfbp3levelsreflecttheheightoutcomeinprepubertalchildrenuponrhghtherapylggrowthstudydatabase AT eunyoungkim investigatingwhetherserumigf1andigfbp3levelsreflecttheheightoutcomeinprepubertalchildrenuponrhghtherapylggrowthstudydatabase AT cheolhwanso investigatingwhetherserumigf1andigfbp3levelsreflecttheheightoutcomeinprepubertalchildrenuponrhghtherapylggrowthstudydatabase AT chanjongkim investigatingwhetherserumigf1andigfbp3levelsreflecttheheightoutcomeinprepubertalchildrenuponrhghtherapylggrowthstudydatabase
_version_	1718439453007020032

Investigating whether serum IGF-1 and IGFBP-3 levels reflect the height outcome in prepubertal children upon rhGH therapy: LG growth study database

Ejemplares similares